Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Noel M, O'Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B, Yin D, Joh T, Jacobs IA, Taylor CT, Lowery MA.

Invest New Drugs. 2019 Jul 12. doi: 10.1007/s10637-019-00830-3. [Epub ahead of print]

PMID:
31297636
2.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.

Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7.

3.

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method.

Boisdron-Celle M, Metges J, Capitain O, Faroux R, Stampfli C, Ferec M, Laplaige P, Lecomte T, Matysiak-Budnik T, Senellart H, Campone M, Morel A, Gamelin E.

Ann Oncol. 2018 Jun;29 Suppl 5:v60-v61. doi: 10.1093/annonc/mdy151.215. Epub 2020 Jan 7. No abstract available.

4.

In reply.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Philippe Metges J, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Apr;44(2):161. doi: 10.1053/j.seminoncol.2017.08.002. Epub 2017 Aug 4. No abstract available.

PMID:
28923216
5.

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.

Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G, Denis F, Zinger M, Juhel-Voog L, Lafond C, Maillart P, Capitain O, Delva R, Soulié P, Abadie-Lacourtoisie S, Guérin-Meyer V, Morin-Meschin ME, Commer JM, Gangler A, d'Aillières B, Zannetti A, Bourbouloux E, Berton-Rigault D, Lebouvier-Sadot S, Kaassis M, Baudon J, Lam YH, Bizieux A, Marcq M, Edeline J, Le Du F, Lefeuvre C, Deguiral P, Delecroix V, Blot E, Egreteau J, Goudier MJ, Lamy R, Ferec M, Artignan X, Corbinais S, Morel H, Hardy-Bessard AC, Alleaume C, Naudeix E, Cojocarasu O, Metges JP, Riché C, Gamelin E, Déniel-Lagadec D, Marhuenda F, Ingrand P, Douillard JY.

Ann Oncol. 2017 Jul 1;28(7):1612-1617. doi: 10.1093/annonc/mdx172.

6.

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.

Boisdron-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):24-33. doi: 10.1053/j.seminoncol.2017.02.007. Epub 2017 Feb 9.

PMID:
28395759
7.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. Epub 2017 Feb 11.

PMID:
28395758
8.

A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.

Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA.

Am J Hematol. 2017 Jul;92(7):660-667. doi: 10.1002/ajh.24736. Epub 2017 Jun 5.

9.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
10.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

PMID:
26615857
11.

Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.

Wu B, Melara R, Rasmussen E, Zhou L, Wong T, Kitahara C, Ma M, Lu J, Gamelin E, Pickett CA, Sun YN.

Cancer Chemother Pharmacol. 2015 Aug;76(2):243-50. doi: 10.1007/s00280-015-2748-1. Epub 2015 Jun 2. Review.

PMID:
26032239
12.

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.

Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S.

Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21.

PMID:
25895965
13.

Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.

Jonchère B, Vétillard A, Toutain B, Lam D, Bernard AC, Henry C, De Carné Trécesson S, Gamelin E, Juin P, Guette C, Coqueret O.

Oncotarget. 2015 Jan 1;6(1):409-26.

14.

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire).

Metges JP, Lebot MA, Faroux R, Riaud F, Gamelin E, Capitain O, Guérin Meyer V, Leynia P, Douillard JY, Senellart H, Rochard S, Louvigné C, Campion L, Dupuis O, Grollier C, Achour NA, Person B, Raoul JL, Boucher E, Bertrand C, Ramée JF, Guivarch L, Etienne PL, Roussel S, Desclos H, Julien MN, Labarre MI, Klein V, Bessard R, Stampfli C, Royet F, Faycal J, Gouva S, Le Bihan G, Couturier M, Gourlaouen A, Bertholom C, Porneuf M, Jobard E, Peguet E, Grasset D, Bouret JF, Bicheler V, Ulvoas A, Miglianico L, Chouzenoux C, Deguiral P, Derenne L, Martin D, Langlet PM, Bodin C, Rossi V, Barré S, Cojocarasu O, Naveau Ploux C, Vidal AM, Cumin I, Egreteau J, Brouard A, Matysiak Budnik T, Thomaré P, Le Bris Michel AS, Piriou G, Largeau R, Elhannani C, Crespeau E, Suberville F, Bourgeois H, Riche C, Lagadec DD, Marhuenda F, Grudé F.

Oncologie (Paris). 2014;16(5):267-276. Epub 2014 Dec 21.

15.

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.

Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, Boisdron-Celle M, Gamelin E, Watier H, Paintaud G, Gouilleux-Gruart V.

MAbs. 2013 Jul-Aug;5(4):614-9. doi: 10.4161/mabs.24815. Epub 2013 Apr 25.

16.

[The role of general practitioner in French cancer centers].

Gangler A, Delva R, Gamelin E.

Bull Cancer. 2013 Apr 1;100(4):323-32. doi: 10.1684/bdc.2013.1734. French.

PMID:
23587722
17.

[Optimizing good use and costs of anticancer drugs: A French inter regional study of the Observatory of Cancer].

Grudé F, Bessard R, Bourgeois H, Douillard JY, Gamelin E, Metges JP, Riché C, Vidal AM.

Bull Cancer. 2013 Mar;100(3):271-82. doi: 10.1684/bdc.2013.1715. French.

PMID:
23518301
18.

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.

Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH.

BMC Cancer. 2012 Sep 29;12:438. doi: 10.1186/1471-2407-12-438.

19.

Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.

Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E.

Clin Colorectal Cancer. 2012 Dec;11(4):263-7. doi: 10.1016/j.clcc.2012.05.004. Epub 2012 Jun 9.

PMID:
22683364
20.

A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.

Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C.

Mol Cell Proteomics. 2011 Dec;10(12):M111.009712. doi: 10.1074/mcp.M111.009712. Epub 2011 Oct 10.

21.

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.

J Cancer Res Clin Oncol. 2012 Jan;138(1):65-72. doi: 10.1007/s00432-011-1061-6. Epub 2011 Sep 30.

PMID:
21960318
22.

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.

Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.

Clin Cancer Res. 2011 Oct 1;17(19):6329-37. doi: 10.1158/1078-0432.CCR-11-1081. Epub 2011 Sep 27.

23.

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

Basseville A, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, Morel A.

Mol Cancer. 2011 Jul 6;10:80. doi: 10.1186/1476-4598-10-80.

24.

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.

Cellier P, Leduc B, Martin L, Vié B, Chevelle C, Vendrely V, Salemkour A, Carrie C, Calais G, Burtin P, Campion L, Boisdron-Celle M, Morel A, Berger V, Gamelin E.

BMC Cancer. 2011 Mar 16;11:98. doi: 10.1186/1471-2407-11-98.

25.

Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.

de Carné Trécesson S, Guillemin Y, Bélanger A, Bernard AC, Preisser L, Ravon E, Gamelin E, Juin P, Barré B, Coqueret O.

J Biol Chem. 2011 Apr 15;286(15):12825-38. doi: 10.1074/jbc.M110.186437. Epub 2011 Feb 3.

26.

Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor.

Courapied S, Cherier J, Vigneron A, Troadec MB, Giraud S, Valo I, Prigent C, Gamelin E, Coqueret O, Barré B.

Mol Cancer. 2010 Aug 3;9:205. doi: 10.1186/1476-4598-9-205.

27.

Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.

Mounier-Boutoille H, Boisdron-Celle M, Cauchin E, Galmiche JP, Morel A, Gamelin E, Matysiak-Budnik T.

Br J Clin Pharmacol. 2010 Aug;70(2):280-3. doi: 10.1111/j.1365-2125.2010.03686.x. No abstract available.

28.

The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition.

Courapied S, Sellier H, de Carné Trécesson S, Vigneron A, Bernard AC, Gamelin E, Barré B, Coqueret O.

J Biol Chem. 2010 Aug 27;285(35):26765-78. doi: 10.1074/jbc.M109.092304. Epub 2010 Jun 1.

29.

Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.

Clavreul A, Piard N, Tanguy JY, Gamelin E, Rousselet MC, Leynia P, Menei P.

J Clin Neurosci. 2010 Jul;17(7):842-8. doi: 10.1016/j.jocn.2009.11.017. Epub 2010 May 13.

PMID:
20466548
30.

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer.

Louvet C, André T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam H, de Gramont A.

J Oncol. 2010;2010:785934. doi: 10.1155/2010/785934. Epub 2010 Apr 8.

31.

[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].

Boisdron-Celle M, Morel A, Gamelin E.

Ann Biol Clin (Paris). 2010 Jan-Feb;68(1):27-32. doi: 10.1684/abc.2010.0394. Review. French.

32.

Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.

Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, Lundell GD, McMillin G, Milano G, Salamone SJ.

Ther Drug Monit. 2009 Dec;31(6):688-94. doi: 10.1519/JSC.0b013e3181b866d0.

PMID:
19935361
33.

A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation.

Ernoult E, Bourreau A, Gamelin E, Guette C.

J Biomed Biotechnol. 2010;2010:927917. doi: 10.1155/2010/927917. Epub 2009 Nov 1.

34.

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne PL, Cadiot G, Mitry E, Smith D, Cvitkovic F, Coudert B, Ricard F, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive (FFCD); Digestive Tumors Group of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

Endocr Relat Cancer. 2009 Dec;16(4):1351-61. doi: 10.1677/ERC-09-0104. Epub 2009 Sep 2.

PMID:
19726540
35.

Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages.

Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P.

Int J Cancer. 2009 Jul 15;125(2):367-73. doi: 10.1002/ijc.24401.

36.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouché O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A.

Ann Oncol. 2009 Apr;20(4):674-80. doi: 10.1093/annonc/mdn680. Epub 2009 Jan 29.

37.

Genetic analysis of acd6-1 reveals complex defense networks and leads to identification of novel defense genes in Arabidopsis.

Lu H, Salimian S, Gamelin E, Wang G, Fedorowski J, LaCourse W, Greenberg JT.

Plant J. 2009 May;58(3):401-12. doi: 10.1111/j.1365-313X.2009.03791.x. Epub 2009 Jan 8.

38.

Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation.

Ernoult E, Gamelin E, Guette C.

Proteome Sci. 2008 Oct 13;6:27. doi: 10.1186/1477-5956-6-27.

39.

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E.

Br J Cancer. 2008 Oct 21;99(8):1239-45. doi: 10.1038/sj.bjc.6604673. Epub 2008 Sep 16.

40.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M.

J Clin Oncol. 2008 May 1;26(13):2099-105. doi: 10.1200/JCO.2007.13.3934. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612.

PMID:
18445839
41.

Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.

Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A.

J Clin Oncol. 2008 Mar 1;26(7):1188-9; author reply 1189-90. doi: 10.1200/JCO.2007.15.3767. No abstract available.

PMID:
18309961
42.

Recurrent priapism related to oxaliplatin infusion.

Adenis A, Mailliez A, Rigot JM, Gamelin L, Vanhuyse M, Gamelin E.

J Clin Oncol. 2008 Feb 20;26(6):1016-7. doi: 10.1200/JCO.2007.15.4849. No abstract available.

PMID:
18281680
43.

The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition.

Vigneron A, Gamelin E, Coqueret O.

Cancer Res. 2008 Feb 1;68(3):815-25. doi: 10.1158/0008-5472.CAN-07-5115.

44.

[Pharmacogenetics of anti-cancer drugs].

Gamelin E, Boisdron-Celle M, Morel A, Capitain O.

Ann Pharm Fr. 2007 Nov;65(6):390-401. Review. French.

PMID:
18079671
45.

[Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects].

Allorge D, Beaune PH, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, Boyer JC, Broly F, Dhaneens CM, Fonrose X, Gagnieu MC, Gamelin E, Gozé C, Jacqz-Aigrain E, Loric S, Loriot MA, Marquet P, Morel A, Namour B, Paintaud G, Peoc'h K, Picard N, Watier H, Verstuyft C.

Ann Pharm Fr. 2007 Nov;65(6):371-81. Review. French.

PMID:
18079669
46.

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.

Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, Gilles S, Boisdron-Celle M, Gamelin E.

Clin Cancer Res. 2007 Nov 1;13(21):6359-68.

47.

A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.

Etienne-Grimaldi MC, François E, Cardot JM, Renée N, Douillard JY, Gamelin E, Bennouna J, Château Y, Milano G.

Clin Pharmacokinet. 2007;46(11):953-63.

PMID:
17922560
48.

Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.

Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M, Jeannin P.

Blood. 2007 Dec 15;110(13):4319-30. Epub 2007 Sep 11.

PMID:
17848619
49.

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.

J Clin Oncol. 2007 Aug 20;25(24):3732-8.

PMID:
17704423
50.

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.

Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E.

Pharmacogenomics J. 2008 Aug;8(4):256-67. Epub 2007 Aug 14.

PMID:
17700593

Supplemental Content

Loading ...
Support Center